Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Danish Carvedilol Study in Portal Hypertension

Phase 3

Completed

Conditions: Cirrhosis
Portal Hypertension

Interventions: Drug: carvedilol
Drug: propranolol

First Posted Date: 2007-06-28

Last Posted Date: 2009-08-10

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 40

Registration Number: NCT00493480

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark

A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

Phase 2

Terminated

Conditions: Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2007-03-08

Last Posted Date: 2016-08-29

Lead Sponsor: Egalet Ltd

Target Recruit Count: 14

Registration Number: NCT00444834

Locations: 🇩🇰
Site 02, Esbjerg, Denmark
🇩🇰
Site 01, Frederiksberg, Denmark

"The Evaluation of Stimulant Withdrawal"

Phase 2

Withdrawn

Conditions: Anxiety
Substance Addiction
Relapse

Interventions: Drug: Coreg

First Posted Date: 2007-03-05

Last Posted Date: 2019-01-31

Lead Sponsor: Aaron J. Janowsky

Registration Number: NCT00442923

Locations: 🇺🇸
US Veterans Hospital, Portland, Oregon, United States

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure

Phase 4

Withdrawn

Conditions: Heart Failure
Chronic Obstructive Airway Disease

Interventions: Drug: Metoprolol
Drug: Carvedilol

First Posted Date: 2006-10-06

Last Posted Date: 2015-06-24

Lead Sponsor: The Alfred

Registration Number: NCT00384566

Locations: 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

Therapy With Verapamil or Carvedilol in Chronic Heart Failure

Phase 4

Conditions: Dilated Cardiomyopathy

First Posted Date: 2006-09-11

Last Posted Date: 2006-09-11

Lead Sponsor: Medical University of Silesia

Target Recruit Count: 100

Registration Number: NCT00374465

Locations: 🇵🇱
Silesian Centre for Heart Disease, 3rd Department of Cardiology, Zabrze, Szpitalna 2 st., Poland

RATe Control in Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Diltiazem
Drug: Verapamil
Drug: Metoprolol
Drug: Carvedilol

First Posted Date: 2006-04-12

Last Posted Date: 2014-05-13

Lead Sponsor: Asker & Baerum Hospital

Target Recruit Count: 80

Registration Number: NCT00313157

Locations: 🇳🇴
Vestre Viken Hospital Trust, Baerum Hospital, Rud, Akershus, Norway

Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

Phase 3

Completed

Conditions: Chronic Heart Failure

First Posted Date: 2006-01-09

Last Posted Date: 2013-02-18

Lead Sponsor: Cardiovascular Clinical Studies

Target Recruit Count: 400

Registration Number: NCT00272805

Locations: 🇺🇸
Idaho Cardiology Associates, Boise, Idaho, United States
🇺🇸
St. Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
Charlotte Heart Group Research Center, Port Charlotte, Florida, United States

and more 48 locations

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

Phase 3

Completed

Conditions: Congestive Heart Failure

First Posted Date: 2005-08-11

Last Posted Date: 2008-12-25

Lead Sponsor: Shaddy, Robert, M.D.

Target Recruit Count: 75

Registration Number: NCT00129363

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University, St. Louis, Missouri, United States

and more 14 locations

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Hypertension
Type 2 Diabetes Mellitus

Interventions: Drug: Carvedilol
Drug: Metoprolol

First Posted Date: 2005-07-25

Last Posted Date: 2014-11-18

Lead Sponsor: St. Paul Heart Clinic

Target Recruit Count: 36

Registration Number: NCT00123604

Locations: 🇺🇸
St. Paul Heart Clinic, St. Paul, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy